Veterinary and IACUC Oversight
Nevivo works with clients to ensure the facility and all research activities are maintained at the highest standards. The company operates in full accordance with the Animal Welfare Act, the PHS Policy on Humane Care and the NRC Guide for the Care and Use of Laboratory Animals. Efforts are ongoing to become accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) – anticipated 2Q2019.
James Macy, Jr, DVM
Professor of Comparative Medicine; Vice Chairman for Clinical Affairs, Comparative Medicine; Attending Veterinarian; Director, Yale Animal Resources Center
Dr. James Macy, DVM, DACLAM received his DVM from the University of Georgia and earned his board certification as DACLAM. He joined Yale University in 1992 as a postdoctoral fellow. Currently, he is professor and Vice Chair of Clinical Affairs in the Department of Comparative Medicine and Director of the Animal Resources Center at Yale University.
Nevivo Senior Management
Nevivo provides comparative medicine research staff with significant pharmaceutical industry experience:
Börk Balkan, Ph.D.
Director of Pharmacology
Dr. Balkan joined Nevivo in 2018, bringing nearly 30 years of scientific leadership and drug discovery experience in the pharmaceutical, biotechnology and consulting industries. Over the course of his career with Novartis, The Institute for Diabetes Discovery and Baphyco, Dr. Balkan has been responsible for in vivo pharmacology, supporting numerous drug discovery programs from early proof-of-concept (POC) studies to clinical development. Dr. Balkan received his doctorate in Physiology from University of Groninggen (The Netherlands) in 1991 for his research on the role of the central and peripheral nervous system in the development of obesity and diabetes. He is a frequent reviewer for a number of scientific journals.
Peter Fowles, LATg
Mr. Fowles is a highly skilled professional with more than 20 years of experience working in academic and commercial vivariums. Before joining Nevivo, Peter conducted various oncology and inflammation models and managed IND enabling studies for Gilead Sciences. Before joining Gilead, he was vivarium manager at CGI Pharmaceuticals where he was responsible for in-life activities supporting multiple drug development programs in a variety of disease models. He has also held positions at Yale University, Charles River Laboratories and Emisphere Technologies.
Michael Van Zandt, Ph.D.
President & CEO
Dr. Michael Van Zandt is an accomplished medicinal chemist and pharmaceutical executive with more than 25 years of combined experience in the CRO and pharmaceutical industries. Before founding Nevivo, Michael founded New England Discovery Partners (NEDP), a sister company and leading contract research organization (CRO) specializing in synthetic and medicinal chemistry. Prior to NEDP, Michael was a senior scientist/project leader/department head/Vice President at The Institute for Pharmaceutical Discovery (IPD) and the pharmaceutical division of Bayer where he played a prominent role in several drug discovery programs that proceeded from high-throughput screening through clinical development.